Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide.

Half year earnings highlight mixed trends for Shandong Weigao Group Medical Polymer

Shandong Weigao Group Medical Polymer (SEHK:1066) has released half year results to 30 June 2026, reporting sales of CNY 6,848.99 million and net income of CNY 774.12 million.

For the same period in 2025, sales were CNY 6,644.05 million and net income was CNY 1,008.32 million. Basic and diluted earnings per share from continuing operations were CNY 0.17, compared with CNY 0.22 a year earlier.

See our latest analysis for Shandong Weigao Group Medical Polymer.

Shandong Weigao Group Medical Polymer's latest half-year earnings arrive after a difficult stretch for investors. The share price is HK$3.48 and the year-to-date share price return has fallen 31.09%. The 1-year total shareholder return is down 47.03% and the 5-year total shareholder return is down 68.36%. This suggests that recent buying interest, including a 6.75% 1-month share price return, contrasts with a longer period in which momentum has faded as the market reassesses the company's earnings profile and risk.

If you are weighing this mixed picture and want to see where capital is shifting in healthcare, it can help to scan a wider set of ideas through the 130 healthcare AI stocks

Shandong Weigao Group Medical Polymer trades at a wide discount to both analyst targets and some fair value estimates, even after the recent rebound. Is the market simply cautious after weaker earnings, or is it pricing the risks correctly?

Preferred P/E of 8.4x for Shandong Weigao Group Medical Polymer: Is it justified?

On the latest close at HK$3.48, Shandong Weigao Group Medical Polymer trades on a P/E of 8.4x, which screens as inexpensive compared with both its peers and the wider Hong Kong Medical Equipment industry.

The P/E ratio compares the HK$3.48 share price with the company's earnings per share and gives you a quick sense of how much investors are paying for each dollar of current profit. For a diversified medical devices group with established product lines across infusion, orthopaedics, pharma packaging and interventional consumables, earnings quality and consistency often matter at least as much as headline growth when judging whether a low P/E is justified.

Here, the picture is mixed. On one hand, Shandong Weigao Group Medical Polymer is assessed as having high quality earnings and trades at what is described as good value compared with peers and the broader industry. On the other hand, recent earnings fell compared with the prior year, net profit margins declined from 15.8% to 12%, and returns on equity are described as low at 6.6%. Forecasts point to earnings growth of 7.32% per year, which is slower than the Hong Kong market, so part of the discount may reflect the market's view on growth and profitability rather than a clear mispricing.